[Economic analysis of adjuvant interferon-alpha-2-therapy in high risk melanoma patients based on results of the ECOG 1684 Study Group].
Hoffmann
W
W
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D018572:Disease-Free Survival; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Wirtschaftlichkeitsanalyse der adjuvanten Interferon-alpha-2b-Therapie bei Hochrisiko-Melanompatienten aufgrund von Ergebnissen der Studie ECOG 1684.